SCHEMBL4998682

SCHEMBL4998682

CCOP(=O)(/C=C/c1ccc([N+](=O)[O-])cc1)OCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.57
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
BCHE P06276 1/20 0.54
ACHE P22303 1/20 0.54
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
APP P05067 1/20 0.49
FBP1 P09467 1/20 0.47
MAOB P27338 1/20 0.47
PTGS1 P23219 2/20 0.47
CYP19A1 P11511 2/20 0.46
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
AKR1C3 P42330 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998683 1.00 PTGS2 (0.57) PTGS2CA1CA2BCHEACHE
SCHEMBL7622684 0.79 CA1 (0.58) PTGS2CA1CA2BCHEACHE
SCHEMBL7622680 0.79 CA1 (0.58) PTGS2CA1CA2BCHEACHE
SCHEMBL8662084 0.78 MAOB (0.42) PTGS2HSD17B10FBP1MAOBNPC1
SCHEMBL8922931 0.78 APP (0.39) CYP3A4TSHRAPPMAOBCYP19A1
SCHEMBL4821195 0.78 NPSR1 (0.36) PTGS2CA1CA2BCHEACHE
SCHEMBL8922929 0.78 APP (0.39) CYP3A4TSHRAPPMAOBCYP19A1
SCHEMBL4821198 0.78 NPSR1 (0.36) PTGS2CA1CA2BCHEACHE
SCHEMBL8662087 0.78 MAOB (0.42) PTGS2HSD17B10FBP1MAOBNPC1
SCHEMBL14244323 0.78 CA12 (0.50) PTGS2CA1CA2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives THERAPHARM GMBH (CH) 2008-12-18 US disclosed
EP-1812453-A1 METHOD OF PREPARING OR SYNTHESIZING POLYAZAMACROCYCLE DERIVATIVES Therapharm GmbH (CH) 2007-08-01 EP disclosed
WO-2006045546-A1 METHOD OF PREPARING OR SYNTHESIZING POLYAZAMACROCYCLE DERIVATIVES THERAPHARM GMBH (CH) 2006-05-04 WO disclosed
US-5670493-A ANGIOGENESIS INHIBITORS ADIR ET COMPAGNIE (FR) 1997-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives POLI, PARP1, DHPS PTGS2 1454/4885CA1 3452/4885CA2 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.